

Longitudinal Neurocognitive, Psychosocial and Health-related Quality of Life Assessment in Advanced Cancer Survivors Treated With Immunotherapy and the Efficacy of Integrative Neurocognitive Remediation Therapy

NCT05667857

Status	RECRUITING
Phase	Not Applicable
Sponsor	Universitair Ziekenhuis Brussel
Enrollment	100 participants

Key Eligibility Criteria

Inclusion (14)

- Non-intervention group:
 - Provision of written informed consent
 - Diagnosed with advanced cancer of any type
 - Initiated immunotherapy (Anti-PD1, Anti-PDL1, CTLA-4, ...) at least one year ago
 - Have a confirmed normalization on whole-body 18F-FDG PET
- ... and 9 more (see full listing online)

Exclusion (1)

- severe co-morbid non cancer-related psychiatric disorders such as psychosis, obsessive compulsive disorders, eating disorders etc., patients with cognitive impairment related to dementia, and patients that are physically or mentally not able to fill in the questionnaires

Locations (2 total)

University Hospital Brugmann, Brussels, Brussels Capital, Belgium
Universitair Ziekenhuis Brussel, Brussels, Brussels Capital, Belgium